CTI Pixantrone Adaptive Trial Interim Data May Allow For 2007 Lymphoma NDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Using an adaptive trial design, Cell Therapeutics uncovered a better than anticipated interim response rate in its Phase III EXTEND study of pixantrone in aggressive non-Hodgkin’s lymphoma.